Bilici, A., Uysal, M., Menekse, S., Akin, S., Yildiz, F., Turan, M., Sezgin Goksu, S., Beypinar, I., Sakalar, T., Değirmenci, M., Erdem, D., Basaran, G., Olmez, O. F., Avci, N., Tural, D., Sakin, A., Turker, S., Demir, A., Temiz, S., Kaplan, M. A., Dogan, M., Tanriverdi, O., Bilgetekin, I., Cinkir, H. Y., Acikgoz, O., Paydas, S., Uslu, R., & Turhal, S. (2022). real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer investigation, 40, 199–209. http://access.bl.uk/ark:/81055/vdc_100148639823.0x000042